

RISK BEHAVIOURS FOLLOWING HEPATITIS C TREATMENT AMONG GAY AND BISEXUAL MEN LIVING WITH HIV IN MELBOURNE, AUSTRALIA

Harney B^{1,2}, Stoové M^{2,3}, Sacks-Davis R^{2,3}, van Santen DK^{2,4}, Fairley C^{5,6}, Medland N^{5,6}, O'Reilly M⁷, Moore R⁸, Tee BK⁹, Sasadeusz J^{1,10}, Iser D^{1,11}, Roney J¹, Hoy J¹, Matthews G¹², Gane E¹³, Prins M^{4,14}, Hellard M^{1,2}, Doyle J^{1,2}

1 Department of Infectious Diseases, Alfred Health & Monash University, Melbourne, VIC, Australia

2 Disease Elimination Program, Burnet Institute, Melbourne, VIC, Australia

3 School of Public Health and Preventive Medicine, Monash University, Melbourne, VIC, Australia

4 Public Health Service of Amsterdam, Amsterdam, The Netherlands,

5 Central Clinical School, Monash University, Melbourne, VIC, Australia

6 Melbourne Sexual Health Centre, Alfred Health, Carlton, VIC, Australia

7 Prahran Market Clinic, Prahran, VIC, Australia

8 Northside Clinic, Fitzroy North, VIC, Australia

9 Centre Clinic, Victorian AIDS Council, St Kilda, VIC, Australia

10 Royal Melbourne Hospital, Melbourne Health, Parkville, VIC, Australia

11 Department of Gastroenterology, St Vincent's Hospital, Melbourne, VIC, Australia,

12 Kirby Institute, University of New South Wales, Sydney, NSW, Australia

13 Auckland City Hospital, University of Auckland, Auckland, New Zealand

14 Infection and Immunity Institute (AI&I), Amsterdam UMC, University of Amsterdam, Amsterdam, The Netherlands

Background: Hepatitis C virus (HCV) elimination among gay and bisexual men (GBM) living with HIV is feasible in many high-income countries. There is concern that risk behaviours following treatment may lead to reinfection and adversely impact HCV elimination goals. We examined risk behaviours prior to and following HCV treatment commencement among sexually active GBM living with HIV.

Methods: Data were drawn from co-EC, a prospective study aiming to treat and eliminate HCV among people living with HIV. Pre and post-HCV treatment commencement changes in self-reported sexual and injecting drug-related behaviours among sexually active GBM attending primary and tertiary care clinics in Melbourne were assessed using McNemar's test. Modified Poisson regression with robust variance was used to examine factors associated with risk behaviours following treatment commencement.

Results: Of 173 males who started treatment, 120 completed a pre and post-treatment commencement questionnaire of who 90 reported ≥ 1 male sex partner before and/or after treatment commencement. Among these 90 sexually active GBM, there was no significant change pre to post-treatment in condom-less anal intercourse with casual partners (52.5%/56.6%, p 0.513) or injecting drug use (41.2%/45.9%, p 0.344), but a significant decrease in group sex (34.4%/21.1%, p 0.011). Post-treatment commencement, condom-less intercourse (adjusted prevalence ratio (aPR) 1.80, 95%CI 1.07-3.03, p 0.026) and group sex (aPR 4.53, 95%CI 1.76-11.67, p 0.002) was highest amongst those who had reported these behaviours pre-treatment. Post-treatment commencement, injecting drug use was associated with the use of crystal methamphetamine during follow-up (aPR 4.36, 95%CI 1.27-14.94, p 0.019).

Conclusion: HCV-related risk behaviours were common among sexually active GBM before and after HCV treatment and primarily occurred among the same men. There was no significant increase in risk behaviours. More frequent post-treatment HCV testing may be justified among GBM engaging in these behaviours to identify potential HCV reinfection and provide prompt re-treatment to prevent further transmission.

Disclosure of Interest Statement: Investigator initiated funding was received from Bristol Myers-Squibb for co-EC. The funders had no input in these analyses or the decision to submit.